




Drug **R**egulation and **I**ncentives for **R**&**D**

The ASEAN Experience

Sauwakon Ratanawijitrasin, PhD

- Pharmaceutical System Research & Intelligence Center (**PSyRIC**)
- Faculty of Pharmaceutical Sciences, Chulalongkorn University
Thailand

The Association of South-east Asian Nations (ASEAN)



ASEAN Members	Drug Regulation 2005	Local Pharm Industry 2005	S&T R&D Expense (% GDP) 1996-2002	S&T Researchers per mil people 1990-2001
Brunei	No market authorization	N	-	-
Cambodia	Y	Y	-	-
Indonesia	Y	Y	-	130
Lao,PDR	Y	Y	-	-
Malaysia	Y	Y	0.4	160
Myanmar	Y	Y	-	-
Philippines	Y	Y	-	156
Singapore	Y	Y	2.1	4052
Thailand	Y	Y	0.1	74
Viet Nam	Y	Y	-	274

ASEAN Pharm Sector

- Mostly generic-formulation industry
- Limited capacity for R&D in most countries
- Limited capacity for drug regulation in most countries

ASEAN Drug Regulation

Drug regulatory frameworks do not discourage R&D

- Regulatory requirements
- Fees
- Time

Brunei vs Singapore

It is unnecessary and counter productive to compromise consumer protection to accelerate availability

Strengthen Drug Regulation

- Risk management
- “ Trusted ” DRAs
- Clear rules, no bureaucracy
- International collaboration

Strengthen R&D

- Government commitment & investment
- Pool international resources for R&D